SCHEMBL367999

SCHEMBL367999

CS(=O)(=O)CCOC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
MGLL Q99685 3/20 0.30
PARL Q9H300 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20672994 0.89 KMT2A (0.30)
SCHEMBL1062744 0.87 PARL (0.32) PARL
SCHEMBL43777 0.87 PARL (0.32) PARL
SCHEMBL16330094 0.86 ALDH1A1 (0.32) ALDH1A1MGLL
SCHEMBL7027419 0.81
SCHEMBL1309141 0.80
SCHEMBL10052377 0.80 ALDH1A1 (0.37) ALDH1A1
SCHEMBL9228581 0.79 PARL (0.31) MGLLPARL
SCHEMBL12237280 0.79 ALDH1A1 (0.44) ALDH1A1
SCHEMBL15218253 0.78 ALDH1A1 (0.38) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1795896-A2 Method for the identification and relative quantification of proteins based on the selective isolation of RRNK peptides for the simplification of complex mixtures of proteins CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CIGB) (CU) 2007-06-13 EP claimed
US-20070128729-A1 Method for the identification and relative quantification of proteins based on the selective isolation of RRnK peptides for the simplification of complex mixtures of proteins CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) 2007-06-07 US claimed
EP-1785729-A2 A method for the selective isolation of multiply-charged peptides applicable in the quantitative proteomics CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CIGB) (CU) 2007-05-16 EP claimed
US-20070099304-A1 Method for the selective isolation of multiply-charged peptides applicable in the quantitative proteomics CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) 2007-05-03 US claimed
WO-1999032080-A2 DEVICE FOR TARGETED IMMOBILIZATION OF THE THROMBOGENIC INHIBITOR HIRUDINE ON POLYMER SURFACES HOECKER HARTWIG (DE) 1999-07-01 WO claimed
US-11591362-B2 Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2023-02-28 US disclosed
US-20210179658-A1 ORTHOGONAL PROTECTING GROUPS FOR THE PREPARATION OF STEREODEFINED PHOSPHOROTHIOATE OLIGONUCLEOTIDES ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2021-06-17 US disclosed
CN-104877127-A Eight-armed polyethylene glycol derivative, preparation method and related biological substance modified by derivative XIAMEN SINOPEG BIOTECH CO LTD 2015-09-02 CN disclosed
US-9095623-B2 Terminally-functionalized conjugates and uses thereof SMARTCELLS, INC. (US) 2015-08-04 US disclosed
US-20140121159-A1 TERMINALLY–FUNCTIONALIZED CONJUGATES AND USES THEREOF SMARTCELLS, INC. (US) 2014-05-01 US disclosed
EP-1752457-B1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2014-03-19 EP disclosed
US-8623345-B2 Terminally-functionalized conjugates and uses thereof Smartcells (US) 2014-01-07 US disclosed
US-6686395-B2 THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-03 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6531495-B1 Potassium channel AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-11 US disclosed
EP-1222163-A1 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS Aventis Pharma Deutschland GmbH (DE) 2002-07-17 EP disclosed
WO-2001025189-A1 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-04-12 WO disclosed
WO-1999032080-A2 DEVICE FOR TARGETED IMMOBILIZATION OF THE THROMBOGENIC INHIBITOR HIRUDINE ON POLYMER SURFACES HOECKER HARTWIG (DE) 1999-07-01 WO disclosed
US-4668797-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1987-05-26 US disclosed
US-4562202-A ANGIOTENSIN CONVERTING ENZYME INHIBITORS HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179658-A1 ORTHOGONAL PROTECTING GROUPS FOR THE PREPARATION OF STEREODEFINED PHOSPHOROTHIOATE OLIGONUCLEOTIDES PCNA, RNGTT, POLL ALDH1A1 4121/4885MGLL 3200/4885PARL 3783/4885
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 ALDH1A1 217/4885MGLL 4306/4885PARL 2125/4885
US-20140121159-A1 TERMINALLY–FUNCTIONALIZED CONJUGATES AND USES THEREOF NPY1R, NTSR1, GRPR ALDH1A1 1525/4885MGLL 4603/4885PARL 3416/4885
US-11591362-B2 Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides PCNA, RNGTT, POLL ALDH1A1 4121/4885MGLL 3200/4885PARL 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.